

## PHARMANUTRA: NEW SALES RECORD IN MAY

**The Group shows significant growth in Italy (+20%) and on foreign markets (+ 48%)**

**Pisa, 28 June 2018** - [PharmaNutra](#) (Aim Italia - Ticker PHN), a leading nutraceutical company in the oral iron products sector, has announced further important results. In May, the Group in fact set a new record for the number of sales compared to the same month in 2017. This significant double-figure growth refers to both the Italian and international markets.

In Italy, sales increased by 20% compared to the same month in 2017, a percentage that is also confirmed by comparing sales relative to the period January-May 2018 with the same period from the previous year (*IQVA data plus direct pharmacy orders*).

The Group has also considerably improved its sales performance on an international level, with a 48% increase from the beginning of the year, compared to the same period from the previous year.

These results take on even more value when you consider the already consolidated leadership of PharmaNutra in the development of nutraceutical products and innovative medical devices on the Italian market.

**Roberto Lacorte, Vice President of PharmaNutra, comments:** *“These are extremely positive figures that we feel must be communicated to our shareholders in order to involve them in our growth path. The results achieved confirm strengthening of PharmaNutra on the Italian and international market, the direct consequence of research and development activity, one of our important strategic assets in which we intend to continually invest to establish the uniqueness of our products.”*

**PharmaNutra S.p.A.**

*Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a Pisa-based enterprise created in 2003 to develop nutraceutical products and innovative medical devices. Representing Italian pharma excellence, the company is present in 38 countries, has 50 direct employees, of which 9 researchers, and a network of 150 single-mandate sales representatives and collaborates with, among others, the Universities of Pisa, Milan, Brescia, Modena, Verona, Barcelona and Brisbane. PharmaNutra is the European mouth-dispersible iron supplement leader with the patented SiderAL product, which in Italy has a 50% market share of the OTC oral iron market. Cetilar was launched on the market in 2017, a formula entirely patented and produced by PharmaNutra, testament to the high quality scientific research undertaken by the Tuscan enterprise.<http://www.PharmaNutra.it>*

*For information:***PharmaNutra S.p.A.**

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
Fax +39 050 7846524  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

**Nomad & Specialist**

**CFO SIM S.p.A.**  
Via dell'Annunciata 23/4  
20121 Milano  
Tel. +39 02 303431  
[ecm@cfosim.com](mailto:ecm@cfosim.com)

**Press Office****Spriano Communication&Partners**

Tel. +39 02 83635708  
Matteo Russo - Cristina Tronconi  
Mob. +39 347 9834881 +39 346 0477901  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)